Breaking Finance News

Auxilium Pharmaceuticals Posts Larger than Expected Losses. EPS Down 300 Percent

Auxilium Pharmaceuticals (NASDAQ: AUXL) reported second quarter adjusted EPS of $(0.44) versus the estimated $(0.21), missing by $0.23. EPS were down 300% year over year. The company reported revenue at $83.0 million versus the estimated $88.52 million. Sales were down 17% from the same quarter last year.

From Yahoo Finance:

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, together with its subsidiaries, develops and markets pharmaceutical products for urology and sexual health worldwide. The company markets Testim, a testosterone gel for the topical treatment of hypogonadism; TESTOPEL, an implantable TRT product; Edex, a injectable drug for erectile dysfunction (ED); Osbon ErecAid, a device for treating ED; STENDRA, a line oral therapy for ED; Striant, a buccal system for testosterone delivery; and XIAFLEX for the treatment of Dupuytren’s contracture in adults with a palpable cord, as well as for the treatment of Peyronie’s.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.